Generic Name and Formulations:
Clonidine HCl 0.1mg, 0.2mg, 0.3mg; tabs.
Boehringer Ingelheim Pharmaceuticals
Indications for CATAPRES:
Initially 0.1mg twice daily. Usual range 0.2–0.6mg daily in divided doses; max 2.4mg/day.
Sinus node dysfunction. AV block. Pheochromocytoma: not effective. Conduction disturbances. Renal dysfunction. Avoid abrupt cessation. If local reaction occurs from patch, using tabs may cause generalized rash. Discontinue 4hrs before surgery; resume as soon as possible after surgery. Patch: remove before defibrillation, cardioversion, or MRI. Pregnancy (Cat.C). Nursing mothers.
Central alpha agonist.
Antagonized by tricyclic antidepressants. Potentiates CNS depressants. Orthostatic regulation disturbances (eg, orthostatic hypotension, dizziness, fatigue) possible with neuroleptics. Monitor heart rate in patients receiving agents known to affect sinus node function or AV nodal conduction (eg, digitalis, calcium channel blockers, β-blockers).
Dry mouth, dry eye, drowsiness, dizziness, weakness, constipation, sedation, rash, myalgia, urticaria, nausea, insomnia, agitation, orthostatic hypotension, impotence, arrhythmias.
Renal and Urology News Articles
- Gadolinium-Based Contrast May Up Acute Kidney Injury Risk in CKD
- Delayed Prostate Cancer Treatment May Up Relapse Risk
- Review: Desmopressin Decreases Nocturia Episodes
- Surgery, Radiation Regimens for High-Grade PCa Offer Similar Outcomes
- Salvage Prostatectomy May Benefit Some Prostate Cancer Patients
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)